Holen Sie sich die Stockscreener-App
877.66
2.08%
-19.34
Handel nachbörslich:
877.00
-0.66
-0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$897.00
Offen:
$896
24-Stunden-Volumen:
2.13M
Relative Volume:
0.71
Marktkapitalisierung:
$784.06B
Einnahmen:
$65.18B
Nettoeinkommen (Verlust:
$20.64B
KGV:
38.85
EPS:
22.5894
Netto-Cashflow:
$5.96B
1W Leistung:
-3.12%
1M Leistung:
-16.50%
6M Leistung:
+21.23%
1J Leistung:
+6.90%
1-Tages-Spanne:
$877.11
$900.83
1-Wochen-Bereich:
$877.11
$926.77
52-Wochen-Spanne:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
877.66 | 801.34B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.36 | 576.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.32 | 373.42B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 294.04B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
188.48 | 284.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly Stock (LLY) Gets a Boost From Latest Trial Results. It Has Nothing to Do with Obesity Drugs - TipRanks
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
Judge Advances Lilly Suit Over Online Platforms’ Mounjaro Copies - Bloomberg Law News
Eli Lilly stock price forecast: bears dominate as LLY consolidates near 200-day support - Traders Union
Clark Foundation, Lilly to partner on new downtown basketball court - Indiana Economic Digest
Morgan Stanley reiterates Overweight on Eli Lilly stock, $1,313 target By Investing.com - Investing.com India
Jefferies reiterates Buy on Eli Lilly stock, $1,300 target - Investing.com
Lilly’s Ebglyss shows four-year efficacy in eczema study - Investing.com
Erste Group Bank Raises Eli Lilly's FY2027 Earnings Forecast - National Today
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis - PR Newswire
AI Models Split on Eli Lilly: Strong Fundamentals, Premium Valuation - TipRanks
Pensionfund Sabic Buys $1.83M Stake in Eli Lilly - National Today
Pensionfund Sabic Makes New Investment in Eli Lilly and Company - National Today
Institutional Investors Are Selling One of Wall Street's Premier Trillion-Dollar Club Members (No, Not Nvidia!) - The Motley Fool
Bath Savings Trust Co Boosts Stake in Eli Lilly - National Today
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
Vanguard disaggregation: Eli Lilly (NYSE: LLY) ownership shows 0 shares - Stock Titan
Why is Eli Lilly stock down today? - Traders Union
The Bull Case For Eli Lilly (LLY) Could Change Following Retatrutide Milestone And Governance ShiftLearn Why - simplywall.st
Eli Lilly stock price forecast: consolidation after recovery as LLY holds above long-term support - Traders Union
Eli Lilly's Sustainability in Pharmaceuticals Strategy - Sustainability Magazine
Assenagon Asset Management S.A. Decreases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Sen. Angus S. King Jr. Sells Off Shares of Eli Lilly and Company (NYSE:LLY) - MarketBeat
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Buy Eli Lilly Stock (LLY) as Employers Move to Cover Obesity Drugs, Says Morgan Stanley - TipRanks
Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer? - Insider Monkey
Assessing Eli Lilly (LLY) Valuation After The Recent Share Price Pullback - simplywall.st
Eli Lilly and the ‘societal obligation’ of GLP-1s - statnews.com
AI Models Split on Eli Lilly: Strong Growth vs. Premium Valuation - TipRanks
Spartan Planning & Wealth Management Buys Shares of 1,556 Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by Dynamic Advisor Solutions LLC - MarketBeat
Biocon To Benefit After Eli Lilly Joins Novo Nordisk To Exit European Insulins Market - NDTV Profit
INNOVENT BIO-Eli Lilly Strategic Collaboration Deal Takes Effect; Rumored Acquisition Intent Not True - AASTOCKS.com
Eli Lilly to phase out select insulin products across Europe by 2027 - MSN
Workforce was region’s secret weapon in winning Eli Lilly | Opinion - PennLive.com
Martin Shkreli Says Silicon Valley's Hottest Health Obsession Is A 'Delusion' - Benzinga
Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study - TipRanks
Barclays Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls - TipRanks
Top Analyst Reports for Eli Lilly, RTX & Abbott - Yahoo Finance
The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant - Yahoo Finance Singapore
Eli Lilly To Phase Out Select Insulin Products Across Europe By 2027 - Benzinga
Massive class action seeking RICO penalties against Takeda, Lilly presses forward with SCOTUS order - Fierce Pharma
Eli Lilly (NYSE:LLY) Sees Institutional Activity in Russell 1000 - Kalkine Media
Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform - insidermonkey.com
Gradient Investments LLC Buys 19,634 Shares of Eli Lilly and Company $LLY - MarketBeat
Hutchens & Kramer Investment Management Group LLC Sells 3,715 Shares of Eli Lilly and Company $LLY - MarketBeat
Grove Bank & Trust Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Decreased by Sarasin & Partners LLP - MarketBeat
Nordea Investment Management AB Raises Stock Position in Eli Lilly and Company $LLY - MarketBeat
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,350 - Moomoo
Eli Lilly Stock: Analysts See 35% Upside, Driven by GLP-1 Demand and Q4 2025 ResultsNews and Statistics - IndexBox
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):